Related Experiment Video
Updated: Jul 27, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
[Effects of MPTP on the mouse retina]
Y Takatsuna1, E Adachi-Usami, H Ino
1Department of Ophthalmology, Chiba University School of Medicine, Japan.
Abstract:
MPTP is known as a selective neurotoxin which destroys dopamine-containing neurons, and induces a model of Parkinson's disease. In the retina, MPTP acts on the amacrine cells which contain dopamine. In the present study, C57BL/6J mice were treated i.p. with MPTP (cumulative dose, 150 mg/kg), and the role of dopamine in the mouse retina was investigated electrophysiologically and immunohistochemically. ERGs were recorded before and 10, 30 and 50 days after MPTP injection. The amplitude of the oscillatory potentials was greatly reduced, and that of the b-wave to a lesser degree, while the a-wave was slightly reduced 10 days after injection. These ERG changes tended to return to the control level 50 days after injection. Immunohistochemical analysis showed that 10 days after MPTP injection the number of tyrosine hydroxylase positive amacrine cells was reduced by approximately 50%, and that these changes had lasted at least until 50 days after MPTP injection.
Insights
MPTP neurotoxin selectively damages retinal amacrine cells, impacting dopamine pathways in Parkinson's disease models. Functional recovery observed in mouse models suggests potential therapeutic insights.
Area of Science:
- Neuroscience
- Ophthalmology
- Pharmacology
Context:
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a potent neurotoxin.
- MPTP selectively destroys dopamine-containing neurons, inducing Parkinson's disease models.
- In the retina, MPTP targets dopamine-containing amacrine cells.
Purpose:
- To investigate the role of dopamine in the mouse retina following MPTP administration.
- To electrophysiologically and immunohistochemically assess the effects of MPTP on retinal function and cell populations.
Summary:
- C57BL/6J mice received MPTP (150 mg/kg cumulative dose).
- Electroretinograms (ERGs) showed reduced oscillatory potentials and b-wave amplitudes 10 days post-injection, with partial recovery by 50 days.
- Immunohistochemistry revealed a ~50% reduction in tyrosine hydroxylase-positive amacrine cells at 10 and 50 days post-MPTP.
Impact:
- Demonstrates MPTP's neurotoxic effects on retinal dopamine pathways.
- Highlights the susceptibility of amacrine cells to MPTP-induced damage.
- Provides insights into functional and cellular changes in an MPTP-induced Parkinson's disease model relevant to retinal function.
